Tag: soliris market forecast

Featuring market attractiveness scoring, total addressable market sizing, company benchmarking matrices, interactive Excel dashboards, deeper supply chain intelligence, emerging startup tracking, and granular product-level insights, The Business Research Company’s 2026 market reports are built to deliver research that is both more actionable and more strategically valuable.

Soliris Market Growth Potential: How Will Market Size Shift Through 2030?

The market size for soliris has experienced robust growth in recent years. It is projected to increase from $2030.44 million in 2025 to $2191.9 million in 2026, at a compound annual growth rate (CAGR) of 8.0%. This historical expansion can be attributed to unmet needs in rare diseases, clinical success in pnh and ahus, regulatory orphan drug incentives, improved patient survival outcomes, and limited therapeutic alternatives.

The soliris market is projected to experience substantial expansion over the upcoming years. Its valuation is anticipated to reach $2941.58 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This projected growth stems from factors such as the broadening scope into more complement-mediated diseases, heightened awareness of rare diseases, advancements in genetic diagnostics, increased financial support for orphan drugs in healthcare, and the implementation of long-term therapy adherence programs. Furthermore, significant developments during this period are expected to include a greater uptake of complement inhibitor treatments, an intensified focus on ultra-rare conditions, the expanded application of long-term biologic treatments, more widespread genetic testing for rare disorders, and the overall expansion of the high-value orphan drug market.

Get A Free Sample Report With In-Depth Market Insights:

https://thebusinessresearchcompany.com/sample_request?id=38864543&type=smp&name=Soliris%20Market%20Report%202026&utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Soliris Market Growth Catalysts And Demand Drivers

The Soliris market is projected to expand due to the rising occurrence of rare blood disorders. These disorders are uncommon conditions impacting the blood’s formation, constituents, or coagulation, including conditions like hemophilia, sickle cell anemia, and thalassemia. The uptick in these disorders can be attributed to better diagnostic techniques, increased public awareness, and both genetic and environmental influences. Soliris aids patients with rare blood disorders by inhibiting the complement protein C5, which prevents overactive complement activation. This action lessens the chance of severe issues such as hemolysis and organ damage, thereby enhancing disease management and patient well-being. For instance, according to NHS England, a government-funded healthcare system in the UK, approximately 17,000 individuals in England were living with sickle cell disease, an inherited blood disorder, in May 2024, with about 250 new diagnoses each year. Consequently, the growing incidence of rare blood disorders is fueling the expansion of the Soliris market.

Soliris Market Driver: Growing Investment In Rare Disease Research Drive Soliris Market Expansion

Increased funding into rare disease research is expected to fuel the expansion of the Soliris market moving forward. The surge in rare disease research investment stems from a heightened awareness of unmet medical requirements, progress in genomics, and the prospect of developing innovative therapies that can enhance patient outcomes. Such investment supports Soliris by broadening knowledge of conditions that lack adequate treatment, thereby increasing the need for potent medical solutions. As an illustration, in July 2023, the Department of Health and Science Care, a UK government department, allocated substantial funds including USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, which links genetic information to clinical features across 50 rare diseases to improve diagnostics and treatment development. Consequently, the escalating investment in rare disease research is propelling the growth of the Soliris market.

Soliris Market Segment Analysis: What Are The Core Market Categories?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Soliris Market Trends Shaping Long-Term Demand

The primary development in the soliris market centers on devising biologic medications for neuromyelitis optica spectrum disorder (NMOSD), aiming to broaden therapeutic choices for rare blood disorders. This signifies a considerable stride in managing NMOSD, a rare and debilitating autoimmune illness affecting the central nervous system, by offering an effective treatment to diminish relapses and guard against further neurological damage. To illustrate, in October 2023, AstraZeneca PLC, a UK-based pharmaceutical company, secured approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China for adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This particular approval represents the first and only complement inhibitor permitted for NMOSD treatment in China.

Soliris Market Top Companies Driving Competitive Growth

Major companies operating in the soliris market are Pfizer

View The Full Soliris Market Report:

https://thebusinessresearchcompany.com/report/soliris-global-market-report?utm_source=Blogs&utm_medium=Paid&utm_campaign=Oct_PR

Soliris Market Regional Analysis: Which Geography Leads On Revenue?

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Reach Out To Our Team:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Enhanced with market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports deliver more actionable and strategically valuable research.

Soliris Market Expansion From $ Billion In 2026 To $ Billion In 2030

The market for Soliris has experienced notable expansion over recent years. Projections indicate an increase from $2030.44 million in 2025 to $2191.9 million by 2026, reflecting a compound annual growth rate of 8.0%. Factors driving the historical growth include the lack of adequate treatments for uncommon diseases, effective clinical outcomes in managing paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome, incentives provided through orphan drug regulations, enhancements in patient survival rates, and the scarcity of competing therapeutic options.

Market analysts project strong growth for the soliris market in the coming years. By 2030, it is anticipated to reach $2941.58 million, driven by a compound annual growth rate (CAGR) of 7.6%. This forecasted expansion can be linked to several factors, including extending its application to additional complement-mediated diseases, heightened awareness of rare conditions, advancements in genetic diagnostics, greater healthcare funding allocated to orphan drugs, and the implementation of long-term therapy adherence initiatives. Key trends shaping this period encompass a growing preference for complement inhibitor therapies, an intensified focus on ultra-rare diseases, the broader utilization of long-term biologic treatments, an increase in genetic testing for rare disorders, and the robust growth of the high-value orphan drug market.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp&utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Soliris Market Growth Drivers: What Factors Are Accelerating Expansion?

Growing frequency of uncommon blood disorders is anticipated to stimulate future expansion of the soliris market. These rare blood disorders involve infrequent conditions that impact blood production, components, or clotting mechanisms, including diseases like hemophilia, sickle cell anemia, and thalassemia. Higher occurrence rates of these disorders stem from enhanced diagnostic methods, increased public awareness, alongside genetic and environmental influences. By blocking the complement protein C5, Soliris aids patients with rare blood disorders in avoiding excessive complement activation, thereby lowering risks of serious complications such as hemolysis and organ damage, which ultimately improves overall disease control and patient health outcomes. For example, in May 2024, the National Health Service (NHS) England, a UK-based government-funded healthcare organization, reported that around 17,000 individuals live with sickle cell disease—an inherited blood condition—in England, with roughly 250 new diagnoses occurring each year. Thus, the rising incidence of rare blood disorders is fueling growth within the soliris market.

Soliris Market Driver: Growing Investment In Rare Disease Research Drive Soliris Market Expansion

Continued expansion of the Soliris market is expected to be driven forward by enhanced financial commitments to rare disease research. This surge in investment is propelled by greater recognition of unmet medical needs, progress in genomic technologies, and prospects for transformative therapies that significantly enhance patient outcomes. Funding directed at rare disease research benefits Soliris by deepening insights into underserved medical conditions, thereby boosting demand for powerful treatment options. As an illustration, in July 2023, the Department of Health and Social Care, a UK-based government agency, allocated major resources, including USD 834.20 million (£790 million) for Biomedical Research Centers, USD 15.06 million (£12 million) to the UK Rare Disease Research Platform, and USD 50.20 million (£40 million) for the NIHR BioResource—which links genetic data with clinical characteristics across 50 rare diseases to accelerate diagnostic and therapeutic progress. Consequently, growing investment in rare disease research is propelling the expansion of the Soliris market.

Soliris Market Segments: Where Are The Largest Growth Opportunities?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Soliris Market Trends: What Is Shaping Future Industry Growth?

A central focus within the soliris market is the advancement of biologic therapies specifically designed for neuromyelitis optica spectrum disorder (NMOSD), aimed at improving treatment outcomes for this rare condition. This development represents a notable milestone in addressing NMOSD, a severe and uncommon autoimmune disorder that impacts the central nervous system, by offering an effective solution that curbs disease relapses and limits ongoing neurological deterioration. To illustrate, during October 2023, approval was granted to AstraZeneca PLC, a pharmaceutical enterprise based in the United Kingdom, for its product Soliris (eculizumab) by China’s National Medical Products Administration (NMPA). This authorization applies to adult patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who test positive for anti-aquaporin-4 (AQP4) antibodies (Ab+), making it the inaugural complement inhibitor to receive such approval for NMOSD management in the Chinese market.

Soliris Market Major Participants And Competitive Dynamics

Major companies operating in the soliris market are Pfizer

Access The Complete Soliris Market Report:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=Jul_PR

Soliris Market Regional Analysis And Leading Geography

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Does The Forecasted Market Size Of The Soliris Market Compare Between 2026 And 2030?

The soliris market size has shown significant growth in recent years. It is forecast to expand from $2030.44 million in 2025 to $2191.9 million in 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. This historical expansion can be attributed to several factors, including unmet needs in rare diseases, successful clinical outcomes in pnh and ahus, regulatory orphan drug incentives, improved patient survival rates, and a limited number of therapeutic alternatives.

The soliris market size is projected to experience substantial expansion over the next few years. By 2030, it is forecast to reach $2941.58 million, growing at a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period is primarily driven by the market’s expansion into more complement-mediated diseases, a heightened awareness of rare diseases, advancements in genetic diagnostics, increased healthcare funding allocated for orphan drugs, and the implementation of long-term therapy adherence programs. Significant trends expected in the forecast period include the increasing adoption of complement inhibitor therapies, a growing focus on ultra-rare diseases, the broader application of long-term biologic treatments, a rise in genetic testing for rare disorders, and the overall growth of the high-value orphan drug market.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

What Are The Main Drivers Accelerating The Growth Of The Soliris Market?

The expanding occurrence of rare blood conditions is projected to boost the growth of the Soliris market in the future. These conditions are unusual ailments impacting the blood’s formation, constituents, or coagulation, including examples like hemophilia, sickle cell anemia, and thalassemia. This increased prevalence stems from better diagnostic methods, heightened awareness, and genetic along with environmental influences. Soliris functions by inhibiting the complement protein C5, thereby assisting patients with rare blood disorders by hindering excessive complement activation. This action lessens the chance of serious issues like hemolysis and organ damage, consequently enhancing overall disease management and patient results. As an illustration, data from May 2024 by the National Health Service (NHS) England, a government-funded healthcare provider in the UK, indicated that roughly 17,000 individuals in England suffer from sickle cell disease, a hereditary blood disorder, with about 250 new diagnoses each year. Consequently, the rising incidence of rare blood disorders is fueling the expansion of the Soliris market. Future expansion of the Soliris market is anticipated to be driven by increasing investments in research on rare diseases. This surge in research funding for rare diseases stems from a growing acknowledgment of unaddressed medical requirements, progress in genomics, and the promise of innovative treatments capable of enhancing patient results. Such investments benefit Soliris by deepening comprehension of conditions that lack adequate treatment, thus stimulating greater demand for efficacious therapies. For example, in July 2023, the Department of Health and Social Care, a UK government body, allocated substantial funding, comprising USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, which links genetic information with clinical characteristics across 50 rare diseases to improve diagnostic and treatment development. Hence, the increasing financial commitment to rare disease research is a key factor propelling the Soliris market’s expansion.

Which Segment-Based Categories Are Covered In The Soliris Market?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

Which Trends Are Influencing The Expansion Of The Soliris Market?

The primary direction within the soliris market involves concentrating on the development of biologic medications for neuromyelitis optica spectrum disorder (NMOSD), intended to improve therapeutic choices for rare blood conditions. This signifies a considerable stride in managing NMOSD, a seldom-seen and debilitating autoimmune disease that targets the central nervous system, by providing an effective therapy designed to minimize relapses and prevent additional neurological damage. For example, in October 2023, AstraZeneca PLC, a pharmaceutical enterprise headquartered in the UK, obtained approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China. This was for the care of adult patients diagnosed with neuromyelitis optica spectrum disorder (NMOSD) who exhibit positivity for anti-aquaporin-4 (AQP4) antibodies (Ab+). This particular approval establishes Soliris as the initial and only complement inhibitor sanctioned for NMOSD treatment across China.

Which Industry Players Are Present In The Soliris Market?

Major companies operating in the soliris market are Pfizer

Access The Complete Soliris Market Report:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Which Region Holds The Largest Share In The Soliris Market?

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795

Asia: +44 7882 955267 & +91 8897263534

Europe: +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Much Will The Market Value Of The Soliris Market Grow Between 2026 And 2030?

The soliris market has shown substantial expansion in recent times. Its valuation is anticipated to rise from $2030.44 million in 2025 to $2191.9 million in 2026, exhibiting a compound annual growth rate (CAGR) of 8.0%. Factors contributing to its historical growth include unmet needs in rare diseases, clinical success in pnh and ahus, regulatory orphan drug incentives, improved patient survival outcomes, and limited therapeutic alternatives.

The Soliris market size is anticipated to undergo significant expansion in the upcoming years. It is projected to achieve a valuation of $2941.58 million by 2030, demonstrating a compound annual growth rate (CAGR) of 7.6%. This anticipated growth during the forecast period can be attributed to several factors, including the broadened application in additional complement mediated diseases, heightened awareness of rare conditions, progress in genetic diagnostics, increased healthcare funding directed towards orphan drugs, and effective long-term therapy adherence programs. Prominent trends expected in this period encompass the increasing adoption of complement inhibitor therapies, a heightened focus on ultra-rare diseases, the wider use of long-term biologic treatments, more prevalent genetic testing for rare disorders, and the expansion of the high-value orphan drug market.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

What Key Drivers Are Fueling The Growth Of The Soliris Market?

The expanding occurrence of rare blood conditions is projected to boost the growth of the Soliris market in the future. These conditions are unusual ailments impacting the blood’s formation, constituents, or coagulation, including examples like hemophilia, sickle cell anemia, and thalassemia. This increased prevalence stems from better diagnostic methods, heightened awareness, and genetic along with environmental influences. Soliris functions by inhibiting the complement protein C5, thereby assisting patients with rare blood disorders by hindering excessive complement activation. This action lessens the chance of serious issues like hemolysis and organ damage, consequently enhancing overall disease management and patient results. As an illustration, data from May 2024 by the National Health Service (NHS) England, a government-funded healthcare provider in the UK, indicated that roughly 17,000 individuals in England suffer from sickle cell disease, a hereditary blood disorder, with about 250 new diagnoses each year. Consequently, the rising incidence of rare blood disorders is fueling the expansion of the Soliris market. Future expansion of the Soliris market is anticipated to be driven by increasing investments in research on rare diseases. This surge in research funding for rare diseases stems from a growing acknowledgment of unaddressed medical requirements, progress in genomics, and the promise of innovative treatments capable of enhancing patient results. Such investments benefit Soliris by deepening comprehension of conditions that lack adequate treatment, thus stimulating greater demand for efficacious therapies. For example, in July 2023, the Department of Health and Social Care, a UK government body, allocated substantial funding, comprising USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, which links genetic information with clinical characteristics across 50 rare diseases to improve diagnostic and treatment development. Hence, the increasing financial commitment to rare disease research is a key factor propelling the Soliris market’s expansion.

What Are The Main Segments Within The Soliris Market Segment Structure?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Trends Are Influencing The Soliris Market?

The principal trend in the Soliris market involves a focus on creating biologic drugs for neuromyelitis optica spectrum disorder (NMOSD) to improve treatment selections for rare blood conditions. This signifies a major step forward in addressing NMOSD, a rare and severe autoimmune condition impacting the central nervous system, by offering an effective therapy to decrease relapses and avoid further neurological harm. For instance, in October 2023, AstraZeneca PLC, a pharmaceutical company located in the UK, secured approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China. This authorization is for the treatment of adult patients in China suffering from neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This makes Soliris the first and only complement inhibitor sanctioned for NMOSD therapy in China.

Who Are The Companies Participating In The Soliris Market?

Major companies operating in the soliris market are Pfizer

Get The Full Soliris Market Report:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Where Is The Soliris Market Most Concentrated Geographically?

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Soliris Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Browse Through More Reports Similar to the Global Soliris Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Membrane Filtration Market Report 2026

https://www.thebusinessresearchcompany.com/report/membrane-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at: marketing@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

The Business Research Company’s 2026 market reports include new capabilities such as market attractiveness scoring and analysis, total addressable market analysis, company scoring matrix, interactive excel data dashboard, improved supply chain analysis, upcoming startups in the market, and overview of key products, aimed at improving the depth, usability, and strategic value of the insights delivered.

What Is The Market Size Of The Soliris Market In 2026 And What Value Is Projected For 2030?

The Soliris market has experienced substantial expansion in recent years. It is forecast to grow from $2030.44 million in 2025 to $2191.9 million in 2026, at a compound annual growth rate (CAGR) of 8.0%. The past growth can be ascribed to unaddressed needs in rare diseases, clinical achievements in PNH and AHUS, regulatory incentives for orphan drugs, improved patient survival outcomes, and limited available therapeutic options.

The soliris market is projected to experience substantial expansion in the coming years, reaching $2941.58 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This anticipated growth stems from factors such as the broadening of treatment areas to include more complement mediated diseases, increasing recognition of rare diseases, advancements in genetic diagnostics, enhanced financial support for orphan drugs in healthcare, and the implementation of long-term therapy adherence initiatives. Key developments expected during this period involve the increasing uptake of complement inhibitor treatments, a heightened emphasis on ultra rare diseases, wider application of long-term biologic therapies, an escalation in genetic screening for uncommon conditions, and the expansion of the high value orphan drug sector.

Download the Free Sample Report to Explore Key Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

What Key Drivers Are Influencing The Growth Of The Soliris Market?

The rising incidence of rare blood disorders is projected to fuel the expansion of the soliris market. These uncommon conditions, which include hemophilia, sickle cell anemia, and thalassemia, impact the blood’s formation, constituents, or coagulation. The surge in these disorders stems from enhanced diagnostic methods, heightened public understanding, and various genetic and environmental influences. Soliris aids individuals with rare blood disorders by blocking the complement protein C5, thereby averting excessive complement activation. This action lessens the chance of severe issues such as hemolysis and organ damage, ultimately enhancing disease control and patient results. As an illustration, data from the National Health Service (NHS) England, a government-funded healthcare provider in the UK, revealed in May 2024 that about 17,000 individuals in England have sickle cell disease, an inherited blood condition, with approximately 250 new diagnoses occurring each year. Consequently, the increasing occurrence of rare blood disorders is stimulating the growth of the soliris market. Increased funding into rare disease research is anticipated to drive the expansion of the Soliris market moving forward. The escalation in rare disease research investment is primarily due to a greater awareness of unaddressed medical requirements, progress in genomics, and the prospect of developing innovative treatments that can better patient well-being. This investment in rare disease research supports Soliris by broadening comprehension of conditions that lack sufficient treatment options, thus boosting the need for potent therapeutic solutions. For example, in July 2023, the Department of Health and Science Care, a UK government body, allocated substantial financial resources, including USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource, which facilitates linking genetic information with clinical characteristics across 50 rare diseases to advance diagnosis and treatment development. Hence, the increasing investment in rare disease research is fueling the Soliris market’s growth.

What Are The Key Segments Of The Soliris Market?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Key Trends Are Influencing The Development Of The Soliris Market?

The central trend in the soliris market revolves around developing biologic medicines for neuromyelitis optica spectrum disorder (NMOSD) to improve treatment options for rare blood disorders. This constitutes a notable advancement in the handling of NMOSD, a rare and severe autoimmune condition impacting the central nervous system, by providing an effective therapy to decrease relapses and prevent further neurological deterioration. For example, in October 2023, AstraZeneca PLC, a UK-based pharmaceutical company, received approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China for the treatment of adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This marks it as the first and only complement inhibitor approved for NMOSD treatment in China.

Who Are The Leading Companies Operating In The Soliris Market?

Major companies operating in the soliris market are Pfizer

Read the full soliris market report here:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Which Region Is Expected To Register The Fastest Growth In The Soliris Market?

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Tailored Soliris Market Research Report For Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19933&type=smp

Browse Through More Reports Similar to the Global Soliris Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Membrane Filtration Market Report 2026

https://www.thebusinessresearchcompany.com/report/membrane-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Uncover key drivers, emerging technologies, and competitive movements shaping the soliris market from 2026–2035 with trusted insights from The Business Research Company

What total market size is anticipated for the Soliris Market in 2030?

The Soliris market size has shown substantial growth over recent years. It is anticipated to expand from $2030.44 million in 2025 to $2191.9 million in 2026, achieving a compound annual growth rate (CAGR) of 8.0%. The expansion observed in the past can be attributed to several factors including unmet needs in rare diseases, successful clinical outcomes in PNH and aHUS, regulatory incentives for orphan drugs, improved patient survival rates, and a limited array of therapeutic alternatives.

The soliris market size is projected to experience significant expansion in the coming years. It is forecast to reach $2941.58 million by 2030, exhibiting a compound annual growth rate (CAGR) of 7.6%. This growth during the forecast period can be attributed to factors such as the expansion into additional complement-mediated diseases, an increase in rare disease awareness, advancements in genetic diagnostics, enhanced healthcare funding for orphan drugs, and the implementation of long-term therapy adherence programs. Prominent trends observed during this period include the rising adoption of complement inhibitor therapies, an increased focus on ultra-rare diseases, the broader use of long-term biologic treatments, more widespread genetic testing for rare disorders, and the overall growth of the high-value orphan drug market.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

What Drivers Are Influencing Production Trends In The Soliris Market?

The Soliris market is projected to grow due to the increasing occurrence of rare blood disorders. These disorders are uncommon conditions affecting the blood’s production, components, or clotting, such as hemophilia, sickle cell anemia, and thalassemia. The rise in their prevalence is attributed to improved diagnostic techniques, greater awareness, and genetic and environmental factors. Soliris aids patients with these conditions by inhibiting complement protein C5, which prevents excessive complement activation. This action reduces the risk of severe complications like hemolysis and organ damage, thereby enhancing overall disease management and patient outcomes. For instance, in May 2024, according to the National Health Service (NHS) England, a UK-based government-funded healthcare system, approximately 17,000 people were living with sickle cell disease, an inherited blood disorder, in England, with around 250 new cases diagnosed annually. Therefore, the increasing prevalence of rare blood disorders is driving the growth of the Soliris market.

Which Segments Are Gaining Traction In The Soliris Market?

The soliris market covered in this report is segmented –

1) By Type: Plasma Exchange, Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH), Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

What Trends Are Projected To Support The Growth Of The Soliris Market?

A significant trend in the Soliris market centers on developing biologic medicines for neuromyelitis optica spectrum disorder (NMOSD), intending to bolster treatment options for rare blood disorders. This constitutes a considerable stride forward in managing NMOSD, a rare and debilitating autoimmune condition affecting the central nervous system, by offering an effective therapy to diminish relapses and prevent further neurological damage. For instance, in October 2023, AstraZeneca PLC, a UK-based pharmaceutical company, obtained approval for Soliris (eculizumab) from the National Medical Products Administration (NMPA) in China for treating adult patients with neuromyelitis optica spectrum disorder (NMOSD) who are positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This establishes Soliris as the first and only complement inhibitor approved for NMOSD treatment in China.

Who Are The Core Companies Influencing Trends In The Soliris Market?

Major companies operating in the soliris market are Pfizer

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Which Regions Are Projected To Dominate The Soliris Market In The Coming Years?

North America was the largest region in the Soliris market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Soliris Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=19933&type=smp

Browse Through More Reports Similar to the Global Soliris Market 2026, By The Business Research Company

Data Lake Market Report 2026

https://www.thebusinessresearchcompany.com/report/data-lake-global-market-report

Market Research Services Market Report 2026

https://www.thebusinessresearchcompany.com/report/market-research-services-global-market-report

Membrane Filtration Market Report 2026

https://www.thebusinessresearchcompany.com/report/membrane-filtration-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Estimated Market Size of the Soliris Market In 2029?

In recent times, the Soliris market has experienced substantial growth. The market size, which is projected to experience growth from $1,880.37 million in 2024, is expected to reach $2,030.44 million by 2025, with a compound annual growth rate (CAGR) of 8.0%. The surge seen in the historical timeline can be traced back to factors such as regulatory permissions, an increase in awareness of rare diseases, a rise in demand for complement inhibition, widened indications, and a boost in the rates of diagnosis.

What Growth Rate Is Forecasted for the Soliris Market by 2029?

The market size of Soliris is anticipated to experience robust growth in the coming years, increasing to $3,734.88 million in 2029 with a Compound Annual Growth Rate (CAGR) of 7.7%. This expansion in the predicted period can be credited to the escalating prevalence of diseases mediated by complement, advancements in gene therapy, growth of market access in newly developing regions, the spread of biosimilars, and enhanced adherence by patients. Dominant trends during the forecast period consist of the endorsement of combination therapies, an upward trend in treatments centered towards patients, a shift towards personalized medical care, an increase in the application of digital health technologies, along with an emphasis on cost-effectiveness and value-based treatment.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

Which Key Companies Are Shaping the Future of the Soliris Market?

Major companies operating in the soliris market include Pfizer

Which Factors Are Driving Demand in the Soliris Industry?

A surge in the incidence of rare blood diseases is anticipated to boost the soliris market’s expansion. Uncommon conditions that affect the production, constituents or coagulation of blood, like hemophilia, sickle cell anemia, and thalassemia, denote rare blood disorders. An increase in the occurrence of these disorders is typically attributed to enhanced diagnostic techniques, heightened awareness, and certain genetic and environmental factors. Soliris works by counteracting the complement protein C5, hence aiding patients with rare blood diseases by preventing an overactivity of complement, which in turn lowers the risk of serious complications like hemolysis and organ damage. This improves overall disease management, resulting in better outcomes for patients. For instance, the National Health Service (NHS) England asserted in May 2024 that nearly 17,000 people in England, living with inherited blood disorder known as sickle cell disease, with roughly 250 new cases being diagnosed every year have in turn contributed to the soliris market boom. The soliris market expansion is also influenced by the escalating investment in the research of rare diseases. The heightened investment in this research is driven by the burgeoning recognition of unmet healthcare necessities, advancements in genomics and prospective breakthrough therapies that can enhance patient outcomes. Increased funding for research on rare diseases encourages the growth of Soliris by enhancing the comprehension of underrepresented disorders, which leads to a rise in the demand for successful treatments. For example, the Department of Health and Science Care in the UK dedicated considerable funding in July 2023, inclusive of USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource. This initiative links genetic data to clinical traits over 50 rare diseases, consequently boosting diagnostic and therapeutic development. Consequently, the escalating investment in research pertaining to rare diseases is stimulating the soliris market’s growth.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=19933&type=smp

How Is the Soliris Market Segmented by Several Divisions?

The solirismarket covered in this report is segmented –

1) By Type: Plasma Exchange; Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

What are the Emerging Market Trends Driving the Growth of the Soliris Industry?

A primary trend emerging in the Soliris market is the increased concentration on the creation of biological medicines intended for neuromyelitis optica spectrum disorder (NMOSD) to improve treatment avenues for uncommon blood disorders. This is indicative of a substantial progression in managing NMOSD, a rare autoimmune condition affecting the central nervous system, by providing an efficacious solution to curb recurrent episodes and safeguard against further neurological impairment. For instance, in October 2023, Soliris (eculizumab) was granted approval by the National Medical Products Administration (NMPA) in China for the treatment of adults with NMOSD who tested positive for antibodies against aquaporin-4 (AQP4). AstraZeneca PLC, a pharmaceutical firm based in the UK, was responsible for this breakthrough. This approval signifies the first-ever endorsement of a complement inhibitor for NMOSD treatment in China.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

Which Regions Are Driving Growth in the Soliris Market?

North America was the largest region in the Soliris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19933

This Report Delivers Insight On:

1. How big is the soliris market, and how is it changing globally?

2. Who are the major companies in the soliris market, and how are they performing?

3. What are the key opportunities and risks in the soliris market right now?

4. Which products or customer segments are growing the most in the soliris market?

5. What factors are helping or slowing down the growth of the soliris market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What External and Internal Drivers Are Contributing to the Growth of theSoliris Market?

The increasing instances of rare blood disorders are anticipated to fuel the expansion of the soliris market in the future. Rare blood disorders entail unusual conditions which affect the production, components, or clotting of blood, such as hemophilia, sickle cell anemia, and thalassemia. The surge in occurrences of rare blood disorders can be linked to advancements in diagnostic technology, higher levels of awareness, and genetic, as well as environmental influences. Soliris works by blocking the complement protein C5 that aids patients suffering from rare blood disorders by averting excessive complement activation, reducing the risk of serious complications such as hemolysis and organ damage which leads to better disease management and improved patient outcomes. For instance, as per the National Health Service (NHS) England, a healthcare system funded by the UK government, it was reported that about 17,000 people in England were living with sickle cell disease, a hereditary blood disorder, with approximately 250 new cases being diagnosed each year. Therefore, the escalating occurrences of rare blood disorders are fostering the growth of the soliris market. The Soliris market’s future is expected to be driven by the rising investment in research on rare diseases. The driving force for investing more in rare disease research is the escalating acknowledgement of unfulfilled medical needs, advances in genomics, and the prospects of pioneering therapies that can enhance patient outcomes. The investment in researching rare diseases aids Soliris by enriching the comprehension of the conditions that are not adequately addressed, leading to an increased demand for efficacious treatments. For instance, in July 2023, the Department of Health and Science Care, a government department based in the UK, offered substantial funding including USD 834.20 million (£790 million) for Biomedical Research Centers, $15.06 million (£12 million) for the UK Rare Disease Research Platform, and $50.20 million (£40 million) for the NIHR BioResource. This connects genetic data to clinical traits across 50 rare diseases, thus contributing to the enhancement of diagnostic and treatment development. Therefore, the amplified investment in rare disease research is fostering the expansion of the Soliris market.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=19933&type=smp

#What is the Growth Potential of the Soliris Market, and How Will It Perform by 2034?

The soliris market has shown robust growth, expanding from $1,880.37 million in 2024 to $2,030.44 million in 2025 at a CAGR of 8.0%. Growth drivers included regulatory approvals, increased rare disease awareness, higher demand for complement inhibitors, more approved uses, and better diagnostic rates.

The soliris market will reach $3,734.88 million in 2029 with a 7.7% CAGR, due to increasing complement-mediated diseases and improved patient compliance. Trends involve combination therapies, personalized care, and digital health growth.

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=19933

Which Upcoming Market Trends and Innovations Are Set to Influence theSoliris Market’s Path Forward?

A prevailing trend in the soliris market revolves around the production of biologic medicines specifically targeting neuromyelitis optica spectrum disorder (NMOSD). This action seeks to expand treatment possibilities for uncommon blood conditions. This progress is noteworthy in NMOSD’s therapy – an infrequent but severe autoimmune disorder targeting the body’s central nervous system, offering a potent treatment to minimize relapses and avert additional neurological impairment. For example, AstraZeneca PLC, a pharmaceutical firm based in the UK, obtained approval for Soliris (eculizumab) in October 2023 from China’s National Medical Products Administration (NMPA) to treat adult patients diagnosed with NMOSD, who have tested positive for anti-aquaporin-4 (AQP4) antibodies (Ab+). This denotes the maiden and sole complement inhibiter approval for NMOSD therapy in China.

Who Are the Dominant Market Players Pushing the Boundaries of theSoliris Market?

Major companies operating in the soliris market include Pfizer

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/soliris-global-market-report

What Are the Core Segments of the Soliris Market, and How Do They Contribute to Growth?

The solirismarket covered in this report is segmented –

1) By Type: Plasma Exchange; Plasma Infusion

2) By Application: Paroxysmal Nocturnal Hemoglobinuria (PNH); Atypical Hemolytic Uremic Syndrome (AHUS)

3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=19933&type=smp

What Regions Are Dominating the Soliris Market Growth?

North America was the largest region in the Soliris market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the soliris market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Browse Through More Reports Similar to the Global Soliris Market 2025, By The Business Research Company:

Paroxysmal Nocturnal Hemoglobinuria (PNH) Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/paroxysmal-nocturnal-hemoglobinuria-pnh-global-market-report

Hemoglobinopathies Treatment Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/hemoglobinopathies-treatment-global-market-report

ACE Inhibitors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/ace-inhibitors-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: